Black Diamond Therapeutics (BDTX) EPS (Basic) Growth (3y) (2021 - 2026)
Black Diamond Therapeutics (BDTX) EPS (Basic) Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | -38.31% |
| 10 | Black Diamond Therapeutics | 125.35 Mn | 14.84 Mn | - | 28.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.36% |
| Mar 31, 2026 | 30.91% |
| Dec 31, 2025 | 20.38% |
| Sep 30, 2025 | 44.51% |
| Jun 30, 2025 | 35.05% |
| Mar 31, 2025 | 49.35% |
| Dec 31, 2024 | 22.02% |
| Sep 30, 2024 | 28.06% |
| Jun 30, 2024 | 14.11% |
| Mar 31, 2024 | 21.60% |
| Dec 31, 2023 | 10.22% |
| Sep 30, 2023 | -11.66% |
| Jun 30, 2023 | -27.65% |
| Mar 31, 2023 | -4.25% |
| Dec 31, 2022 | 49.57% |
| Sep 30, 2022 | 26.35% |
| Jun 30, 2022 | 37.59% |
| Mar 31, 2022 | 27.43% |
| Dec 31, 2021 | 40.91% |